IRAK4 degraders for MYD88 mutant lymphoma

June 18, 2019

International Conference on Malignant Lymphoma (ICML)

6.18.19
Area of Focus
Oncology
Programs
IRAKIMiD (KT-413)
Indications
MYD88 Tumors
Development Stage
Pre-clinical Data
Share
LinkedInXFacebookEmailCopy Link